Skip to main content
. 2009 Jan 14;80(5):1072–1080. doi: 10.1095/biolreprod.108.073908

FIG. 2.

FIG. 2.

Effect of SMAD2/3 inhibition in the presence of FSH/EGF during IVM on fetal and placental outcomes. Day 4.5 blastocysts developed from COCs matured in the DMSO (0.04% [v/v]) control or with 4 μM SB-431542 in the presence of FSH (50 mIU) and EGF (10 ng/ml) were transferred to pseudopregnant recipients, and outcomes were analyzed on Day 18 of pregnancy. Black and white bars represent embryos derived from oocytes matured with the DMSO carrier control and SB-431542 treatment, respectively. Data represent percentage of mean fetal crown-to-rump length (A), fetal:placental weight ratio (B), and fetal and placental weight (C) ± SEM of 12–21 fetuses/placentas in seven replicate experiments. N = 42 embryos transferred per treatment.